It is a copyrighted instrument, which has been translated and validated into 81 languages and is used in more than 3,000 studies worldwide. Presently QLQ-C30 Version 3.0 is the most recent version and should be used for all new studies.
It is supplemented by disease specific modules e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer and Multiple Myeloma which are distributed from the Data Center. Other disease specific modules are under development but not yet validated.
We have also developed a Satisfaction with Care measure (EORTC-IN-PATSAT32) and a Palliative Care questionnaire (QLQ-C15-PAL). These are also general questionnaires.
Conditions for its use are dependent on whether it will be employed in an academic or commercial setting. For academic settings, there is no charge, but a User's agreement is required for each study (please go to 'Downloads' to fill in a download request).
For studies carried out on behalf of a commercial sponsor a royalty fee is payable. A royalty fee is required per study. The amount of the fee depends on the number of patients. For further details of the fee structure, please contact Sarah Williams.
The funds that are generated through the copyright arrangement are used exclusively to support the on-going research of the QLG on the development and refinement of quality of life instruments.
For further information contact Ken Cornelissen (for academic studies) and Sarah Williams (for commercial studies).
Can I see a copy of the QLQ-C30?
A specimen of the QLQ-C30 is available by clicking here.
What are the available translations?
You can see a list of the available translations by clicking here.
How can I employ the QLQ-C30 in my study?
If your study is purely academic you can download the QLQ-C30 and validated modules by clicking here. You will be asked to complete a 'User's Agreement' form before commencing your study.
If your study is carried out by a commercial sponsor, or if your study is being partially sponsored by the pharmaceutical industry, please contact Sarah Williams directly.